Direct patient access Phenomix Sciences has launched direct-to-consumer access to its MyPhenome genetic obesity test, enabling online ordering and personalized lifestyle and treatment guidance. This creates upsell opportunities with healthcare providers who can integrate MyPhenome results into treatment plans.

Clinical utility validation Recent and upcoming presentations at Obesity Week and DDW, plus a proprietary genetic risk score, reinforce the test’s predictive value across diverse populations. This supports marketing to payers, health systems, and employers as a precision obesity solution that can reduce treatment variability.

Strategic partnerships Existing integrations with InformedDNA and collaborations with Mayo Clinic position Phenomix as a gateway to payer networks, health systems, and life sciences organizations. Leverage these relationships to broaden distribution, co-marketing, and bundled offerings.

Three-in-one offering The MyPhenome suite including Hungry Gut, Hungry Brain, and Emotional Hunger provides a comprehensive phenotyping tool. This enables cross-sell to digital health platforms, nutritionists, behavioral health services, and pharmaceutical weight-loss interventions seeking personalized therapy matching.

Market and funding signals With estimated revenue in the mid tens of millions and a lean employee base, Phenomix targets scalable growth through enterprise sales to clinics, payers, and employers, while highlighting its technology stack and cloud-ready capabilities for rapid integration.